logo-loader
viewPharmaxis Ltd

Pharmaxis reveals a quarterly shareholder update full of highlights

Pharmaxis Ltd (ASX:PXS) chief executive Gary Phillips discusses with Proactive Investors the highlights contained within the biotech company’s latest Quarterly Shareholder Update.


“The one thing which really caught everyone’s attention was Boehringer Ingelheim starting a second indication with the drug they licensed from us,” notes Phillips. That development garnered a $15 million milestone payment.


Meanwhile, two compounds from the anti-fibrotic LOXL2 program have entered the clinic for phase one testing. The quarter also saw sales of Bronchitol improve in Europe and Australia.

Quick facts: Pharmaxis Ltd

Price: 0.105 AUD

ASX:PXS
Market: ASX
Market Cap: $41.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Pharmaxis Ltd expects review of Bronchitol NDA to be completed by mid-2020

Pharmaxis Ltd (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) CEO Gary Phillips speaks to Proactive's Andrew Scott after it was announced its US licensee Chiesi Farmaceutici SpA filed a resubmission to the FDA for Bronchitol® . The move addresses issues raised by the US Food and Drug Administration (FDA)...

on 6/5/20

2 min read